Medicare Launches GLOBE Model to Tame Drug Price Hikes
Published Date: 10/2/2026
Rule
Summary
Starting November 30, 2026, Medicare will use the new GLOBE Model to help lower the cost of certain drugs for people on Original Medicare. This model changes how drug price increases are calculated, aiming to save money for both patients and the Medicare program without cutting care quality. If you’re on Medicare Part B, expect smarter drug pricing that helps keep your healthcare affordable.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 1 costs, 0 mixed.
Selected Medicare beneficiaries pay less coinsurance
About 25 percent of Original Medicare (OM) Part B beneficiaries in randomly selected ZIP Code Tabulation Areas (ZCTAs) will be placed in the GLOBE Model cohort and may pay reduced coinsurance for certain Part B drugs. The model begins collecting data January 1, 2027, performance years run April 1, 2027 through March 31, 2032, and beneficiary coinsurance is computed using the lesser of the GLOBE benchmark amount or the inflation-adjusted payment amount (the rule gives an example where coinsurance could be reduced from 20% to 10%).
Medicare program expects multi-year cost savings
CMS estimates the GLOBE Model will reduce Medicare Part B net spending by $440 million over the 7-year payment period (April 1, 2027 through March 31, 2034), including $298 million in Original Medicare Part B benefit savings, $288 million in Medicare Advantage payment savings, and a $147 million premium offset impact; the rule also estimates $39 million in Medicaid savings over the period.
GLOBE applies only to specific high‑spend Part B drugs
The model will apply to a subset of Part B rebatable single-source drugs and sole-source biological products within specified USP categories (Antigout Agents, Antineoplastics, Blood Products and Modifiers, Central Nervous System Agents, Immunological Agents, Metabolic Bone Disease Agents, and Ophthalmic Agents). To be included, a drug must have OM Part B spending greater than $100 million over a 12-month period ending 6 months before the start of the applicable calendar quarter; the rule also lists explicit exclusions (for example, drugs subject to Medicare Drug Price Negotiation, drugs designated for rare diseases under 21 U.S.C. 360bb, FDA-listed cellular and gene therapy products, and plasma-derived products).
Manufacturers must pay GLOBE rebates; data collection starts January 2027
Manufacturers of Part B rebatable drugs that are GLOBE Model drugs are mandatory model participants and will be required to pay incremental GLOBE Model rebates when the benchmarked amount exceeds the statutory inflation-adjusted payment amount. CMS will begin collecting voluntary manufacturer-submitted international drug net pricing data on January 1, 2027, and the model uses two benchmark methods (Method I using commercial international price sources and Method II using manufacturer-submitted net prices). The set of reference countries includes Australia, Canada, France, Germany, Japan, the United Kingdom, and others listed in the rule.
Providers must reduce beneficiary coinsurance and will receive adjusted payments
Providers and suppliers who furnish GLOBE Model drugs to GLOBE Model beneficiaries will continue to bill and be paid under Medicare Part B, but when reduced beneficiary coinsurance applies the provider must lower the coinsurance charged and Medicare’s program payment to the provider will be adjusted upward accordingly (the rule gives an example where a $100 allowed amount with coinsurance reduced from 20% to 10% yields a Medicare payment of $90 and beneficiary responsibility of $10). Providers are not model participants and beneficiary selection and rebate determinations are not subject to appeal.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-22792, Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
Starting in 2029, Medicare will negotiate drug prices to help lower costs for people using Medicare Part D. This new rule, effective December 5, 2026, sets clear policies to make prescription drugs more affordable and fair. If you or a loved one uses Medicare for prescriptions, expect some savings and changes in how drug prices are set.
2026-22750, Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Policies
Starting in 2027, Medicare is updating how it pays home health agencies, including new payment rates and rules to make care better and fairer. Home health providers, equipment suppliers, and Medicare enrollees will see changes in payment methods, quality reporting, and equipment rules, with some new deadlines and expanded benefits. These updates aim to improve care quality while keeping payments clear and fair.
2026-22743, Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program
Starting January 1, 2027, Medicare and Medicaid are updating how doctors and clinics get paid to better match real medical work and new laws. This includes new rules for drug price rebates, sharing savings programs, and payment updates for rural clinics and ambulance services. These changes affect doctors, patients, and healthcare providers, aiming to keep care fair, affordable, and up-to-date.
2026-22739, Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots
Starting in 2027, Medicare is updating how hospitals and surgery centers get paid for outpatient care and surgeries. These changes affect hospitals, surgery centers, and patients by adjusting payment rates and improving quality reporting. Plus, CMS is asking for ideas to make hospital price info clearer and easier to compare, while also handling rules about emergency care and teaching hospital closures.
2026-22381, Medicare and Medicaid Programs; Organ Procurement Organizations Conditions for Coverage: Revisions to the Conditions for Coverage
This new rule updates how Organ Procurement Organizations (OPOs) operate to help get more life-saving organs to people who need transplants. It changes some definitions, competition rules, and appeal processes to make OPOs work better and be held accountable. These changes start January 4, 2027, and aim to save more lives without adding extra costs.
2026-22194, Medicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury (AKI) Dialysis Payment, and ESRD Quality Incentive Program
Starting January 1, 2027, Medicare is updating how it pays for kidney dialysis treatments for people with End-Stage Renal Disease (ESRD) and those with Acute Kidney Injury (AKI). These changes include new payment rates and updated quality rules to make sure patients get the best care. If you’re a dialysis provider or patient, expect some shifts in payments and quality standards that aim to improve treatment and support innovation.
Previous / Next Documents
Previous: 2026-20276, State of Indiana: Discontinuance of Certain Commission Regulatory Authority Within the State, Notice of Agreement Between the Nuclear Regulatory Commission and the State of Indiana
Starting September 30, 2026, Indiana will take over certain nuclear material safety rules from the U.S. Nuclear Regulatory Commission. This means the state now handles the rules for some radioactive materials that aren’t enough to cause a nuclear reaction. This change helps Indiana manage its own safety standards without extra federal oversight.
Next: 2026-20324, Special Local Regulation; Allegheny River Mile Marker 20.5-21, Creighton, PA
On October 10, 2026, from 8 a.m. to 4 p.m., the Coast Guard will temporarily block off a section of the Allegheny River near Creighton, PA, for a paddle boat race. Only authorized boats can enter this area to keep everyone safe and avoid accidents. If you’re boating nearby, plan ahead to avoid delays and enjoy the race from a safe distance!